Nifurtimox is an antiparasitic drug used for the treatment of Chagas disease (Trypanosoma cruzi infection). Chagas disease, caused by a parasite known as Trypanosoma cruzi (T.cruzi), is a vector-transmitted disease affecting animals and humans in the Americas.
- Mechanism
- Curator reviewed · 4 references
The mechanism of action of nifurtimox has not been fully elucidated, however, is believed to occur by the activation of nitroreductase enzymes that produce reactive metabolites with a series of deleterious effects on Trypanosoma cruzi, the parasite causing Chagas disease. The antiprotozoal actions of nifurtimox occur both intracellularly and extracellularly. Inhibition of parasite dehydrogenase activity is another purported mode of action of nifurtimox that warrants further research.
- Primary indication
- Nifurtimox is indicated in pediatric patients under 18 weighing at least 2.5 kg.Curator reviewed · 1 structured indication
- Formula / weight
- C10H13N3O5S · 287.29 g/mol (avg)
- First approval
- United States, 2020
- Code names
- BAY-2502 · BAY-A2502 · BAYER-2502 · CCRIS 2201 · DNDI1613515
- Brand names
Resolves to
ARFHIAQFJWUCFH-IZZDOVSWSA-NSMILESCC1CS(=O)(=O)CCN1\N=C\C1=CC=C(O1)[N+]([O-])=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Nifurtimox, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account